Estudo randomizado | Deucravacitinibe vs. placebo vs. apremilaste na psoríase em placas moderada a grave.
18 Jul, 2022 | 13:14hDeucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial – Journal of the American Academy of Dermatology (link para o resumo – $ para o texto completo)